BioNTech Unleashes $1 Billion Buyback as Cancer Pipeline Takes Center Stage

BioNTech is putting its money where its mouth is. The Mainz-based biotech formally activated a $1 billion share repurchase programme on May 7, deploying its massive cash reserves to signal confidence even as its COVID-19 vaccine franchise continues to shrink. The buyback, which covers American Depositary Shares and runs until May 6, 2027, represents up to 4.2 percent of outstanding equity — a meaningful capital return from a company in the midst of a strategic overhaul.

The move comes on the heels of a first quarter that laid bare the transition pains. Revenue slumped more than 35 percent year-on-year to €118.1 million as demand for pandemic-era jabs faded. BioNTech booked a net loss of $622 million for the period, driven by research and development spending that topped $650 million as the company pours resources into its oncology pipeline. On a per-share basis, the loss of $2.26 still managed to beat analyst expectations, offering a sliver of comfort.

Yet the balance sheet remains formidable. At the end of March, BioNTech held €16.8 billion in cash and securities — a war chest that gives management ample room to fund both the buyback and its ambitious cancer research agenda. Chief Financial Officer Ramón Zapata framed the repurchase as a vote of confidence in the company’s long-term trajectory, emphasising a disciplined approach to capital allocation as BioNTech works toward self-sustaining growth.

Should investors sell immediately? Or is it worth buying BioNTech?

The stock has had a rocky week, shedding roughly 10 percent and trading at around €79.25 — well below its 50-day moving average. Friday brought some relief, with shares climbing 2.3 percent to roughly €81 on the buyback news, though the seven-day picture remains negative by more than 8 percent. Analysts are split on the outlook. Goldman Sachs reiterated its buy rating in March, while Leerink Partners downgraded the stock from outperform to market perform with a $113 price target, citing uncertainty around the pace of oncology monetisation and an impending leadership change.

All eyes are now on the data calendar. BioNTech has described 2026 as a year rich with clinical readouts. The upcoming ASCO annual meeting, starting May 29, will feature new results from the ROSETTA Lung-02 study. Later in the year, interim data from the PRESERVE-003 trial for the antibody Gotistobart are expected — a candidate that has already shown a 54 percent reduction in mortality versus standard chemotherapy in a phase 3 interim analysis. Five additional registration-enabling studies for the drug Pumitamig, developed in collaboration with Bristol Myers Squibb, were launched this year.

A milestone payment of €613 million from a partnership is anticipated in the third quarter, which should provide a meaningful boost to the revenue line. Meanwhile, Pfizer is set to take over full COVID-19 vaccine manufacturing capacity from BioNTech by the end of 2026, gradually relieving the company of pandemic-era infrastructure costs. The buyback alone won’t reverse the stock’s recent slide, but the coming months will test whether the oncology pipeline can deliver the substance that management has been promising.

Ad

BioNTech Stock: New Analysis - 8 May

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...

en | US09075V1026 | BIONTECH | boerse | 69294463 |